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Abstract
Farrell, Amy Susan. Ph.D. The University of Memphis. August 2018. Characteristics
of Smoking Oncology Patients in a Community Cancer Center: A Study of Individual
Differences. Major Professor: Leslie A. Robinson, Ph.D.

Cigarette smoking can seriously impede cancer treatment and leads to poorer treatment
response. Fortunately, even when patients have cancer, smoking cessation has significant
benefits. However, there have not been many successful well-controlled studies assessing
smoking cessation interventions in oncology settings. The present study aimed to expand upon
the current literature by exploring sample characteristics and individual differences in this
understudied population. Data were collected from 649 adult participants at a mid-South
community-based cancer center. Three measures were developed and subjected to factor analysis
to assess level of health literacy, perceived stigma, and oncology-related triggers in this sample.
These variables were then used as the dependent variables for three separate General Linear
Models to determine whether scale scores varied by ethnicity, gender, smoking level, and
whether the participant was a cancer survivor or currently in treatment. Each measure
demonstrated adequate internal consistency and produced a single factor. Females were more
likely than males to experience more smoking triggers when faced with cancer symptoms or
treatments. Caucasians were more likely than African Americans, and lower level smokers were
more likely than heavy smokers, to have higher health literacy. No individual differences were
found within perceived stigma scores. Several implications of this research should be
acknowledged. First, each scale demonstrated strong internal consistency in an oncology patient
sample, making them appropriate for use in future research and confirming their utility in a
clinical setting. Second, women were more likely than men to experience increased triggers to
smoke when faced with oncology-related stress. They may need more support from medical and
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mental health staff to address cravings and to ensure their cigarette consumption does not
increase. Third, smoking-related health literacy levels were high overall, indicating that patients
are aware of the health consequences of smoking. However, these participants continued to
smoke even though they realized that they are less likely to have successful treatment outcomes.
Further, health literacy varied by both ethnicity and smoking level, but patients scored high on
health literacy overall. This may indicate the need for motivational enhancement strategies to
increase motivation to quit among African Americans and heavier smokers.
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Characteristics of Smoking Oncology Patients in a Community Cancer Center: A Study of
Individual Differences
Cigarette smoking is the leading cause of preventable death and disease in the United
States today with an estimated 480,000 people prematurely dying each year as a result of
smoking (US Department of Health and Human Services [USDHHS], 2014). Tobacco-related
health care expenditures in the U.S. total $289 billion in direct medical costs and lost
productivity each year (Jamal et al., 2014). This is due, in part, to the high rates of smokingattributable conditions such as chronic bronchitis, emphysema, heart attack, stroke, cancer, as
well as various pulmonary and neurological diseases (USDHHS, 2014). Still, an estimated 42.1
million adults in the United States continue to smoke (Jamal et al., 2014). Given these high rates
of smoking, more research is needed to decrease the health impact of smoking in the U.S.,
particularly among vulnerable populations.
The consequences of smoking in terms of cancer onset and progression are well
documented. Smoking increases the risk of dying from cancer and is directly related to one out
of every three cancer deaths in the United States (USDHHS 2014). Cigarette smoking damages
virtually all organs of the body and reduces overall health (CDC, 2015). Smoking is associated
with significant increases in the development of numerous forms of cancer, including bladder,
blood, cervix, colorectal, esophagus, kidney and ureter, larynx, liver, oropharynx, pancreas,
stomach, and trachea, bronchus, and lung cancers (USDHHS, 2014). Over 85% of the
approximately 53,000 U.S. cases of head and neck cancer are associated with smoking. Over
90% of lung cancer cases are directly attributable to smoking and between 60% to 70% of cases
for other smoking-related cancers (Burns, Garfinkle, & Samet, 1997). Smokers are also at higher
risk of having metastatic disease at diagnosis (Kobrinsky, Klug, Hokanson, Sjolander, & Burd,
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2003). Further, patients who smoke are at increased risk of developing a second malignancy at
either the same or a different tumor site, regardless of whether or not they initially presented with
a smoking-related malignancy (Gritz et al., 2006; Parsons, Daley, Begh, & Aveyard, 2010).
Cigarette smoking can seriously impede cancer treatment, as it leads to poorer treatment
response. Smoking can reduce treatment effectiveness and worsen the side effects of treatment
(Chen et al., 2007; Des Rochers, Dische, & Saunders, 1992; Geyer et al., 2010; Kawahara et al.,
1998). Further, smoking cigarettes can lead to immunosuppression and have a negative impact
on wound healing, which is of particular concern for surgical patients (USDHHS, 2010a;
USDHHS, 2010b). The ability to heal is repressed in smokers due to vasoconstriction, inhibition
of epithelization, and creation of cellular hypoxia caused by both carbon monoxide and nicotine
(Gritz, Kristeller, & Burns, 1993; USDHHS, 2004). In head and neck cancer patients, surgical
and long-term complications are much more likely to occur for patients who smoke (Wein,
2009). Additionally, smokers with acute myeloid leukemia who receive induction
chemotherapy have an increased risk of developing severe pulmonary infection than those who
do not smoke (26% vs 18%) (Chelghoum, 2002). Finally, patients who continue to smoke
during radiation therapy have lower rates of both complete response to treatment (45% vs. 74%)
and survival at 2 years post-treatment (39% vs 66%) (Kearney, Lee, Reilly, DeCamp, &
Sugarbaker, 1994).
Fortunately, even when patients have cancer, smoking cessation has significant benefits.
In patients with primary cancers, smoking cessation is associated with a decreased risk of a
second malignancy and decreased mortality (Chen et al., 2007; Geyer et al., 2010; Kawahara et
al., 1998). Further, the risks for developing mouth, throat, esophagus, and bladder cancers are
lowered by 50% within 5 years of quitting smoking, and the risk of dying of lung cancer drops

2

by half 10 years after quitting (USDHHS, 2010b).
An estimated 68.8% of smokers overall would like to quit, and 4 out of 10 have made a
quit attempt in the past year (CDC, 2011; USDHHS, 2014). Of those who relapse, nearly two
thirds would like to make another quit attempt within 30 days (CDC, 2002). Oncology patients
in particular are most likely to quit at diagnosis. Several studies suggest quit rates of over 50%
for smokers with cancer during this timeframe (Day et al., 1994; Duffy et al., 2008; Spitz,
Fueger, Chamberlain, Goepfert, & Newell, 1990), with one study reporting that newly diagnosed
patients quit at rates five times higher than the general population (Bassett et al., 2012). It has
been recommended that the diagnosis of cancer be used as a ‘teachable moment’ to increase
motivation for quitting and increase cessation rates overall (Gritz et al., 2006).
Many smokers quit on their own when faced with a cancer diagnosis. However,
researchers are concerned about those who do not try to quit as well as those who try to quit but
do not succeed. These ‘diehard’ smokers are often unable to quit even when faced with cancer.
One 2009 study by Martinez and colleagues highlighted the difficulties in recruiting cancer
patients into smoking cessation programs. Among smoking participants, 16% (N = 43) refused
enrollment and 84% (N = 220) consented. Barriers that significantly impeded enrollment
included medical contraindications (5.0%), not being interested in quitting (4.0%), participants
not being reachable by telephone (4.0%), medication contraindications (1.0%), mortality (0.8%),
transportation issues (0.7%), non-English speaker (0.7%), low-level smoking below the study cut
off (0.3%), psychiatric history (0.1%) and ‘other’ (0.4%). Ethnicity, age, and gender were not
associated with enrollment status. However, those with bladder, cervical, colorectal, kidney,
lymphoma, and ovarian tumor sites had higher refusal rates than those presenting with head and
neck, lung, breast, and prostate cancer patients. Those with more advanced disease were also
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more likely to decline enrollment. Patients who enrolled tended to have smoked for prolonged
periods (m = 38 years) and were highly dependent on nicotine.
Unfortunately, there have not been many successful well-controlled studies assessing
smoking cessation interventions in oncology settings. Recently, Nayan et al. (2013) provided a
thorough review of the smoking cessation intervention literature for 10 randomized controlled
trials and three prospective cohort studies in smoking oncology populations. Interventions
included nicotine replacement therapy (NRT), bupropion, varenicline, and counseling. The
authors found that for both short-term and long-term follow-up studies, tobacco cessation
interventions did not significantly affect quit rates regardless of intervention components used,
except in the perioperative period. The authors hypothesized that some predictive factors may
not have been detected due to small effect sizes. Recommendations for future interventions
included using more intensive pharmacotherapy interventions in conjunction with counseling
while collaborating with patients’ healthcare team to coordinate care.
Since Nayan’s 2013 review, the field has continued to struggle to develop effective
smoking cessation programs for cancer patients. Ostroff and colleagues (2014) found no
significant cessation rate differences at 6-month follow-up between participants who were
treated with NRT and counseling when compared with participants receiving NRT, counseling,
and scheduled reduced smoking training. Kehlet, Heeseman, Tonnesen, & Schroeder (2015)
conducted a single-blind clinical trial that randomized cancer patients to a 6-week motivational
and educational intervention condition or a standard care control condition. Though the study
was underpowered due to recruitment difficulties, no statistically significant difference in
cessation rates was observed between the two conditions at 6-week follow-up. More research is
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needed to address potentially important factors for why cessation interventions in this population
have not been effective.
Perceived Stigma
For optimal results, cessation interventions should be flexible and tailored to the
individual. Gritz and colleagues (2006) noted that cancer-related issues must be considered, as
smoking cessation approaches may need to be adapted to the physical limitations often
experienced during the course of disease and treatment. The authors also emphasized the
importance of attending to psychological factors and disease-related stress, which can hinder
cessation. One important factor is the guilt, shame, and stigma that often surrounds cancer
patients who smoke. Particularly for those with smoking-attributable cancers, patients may feel
blamed and stigmatized for their disease, a situation that may delay medical treatment, cessation
services, and seeking support from loved ones (Carter-Harris, 2015; Chapple, 2004; Marlow,
Waller, & Wardle, 2015). It is therefore not surprising that social support has long been
identified as an important factor that can influence smoking treatment outcomes (Cobb, Graham,
Bock, Papandonatos, & Abrams, 2005). However, previous studies have lacked attention to
these important psychosocial factors.
Oncology-Related Smoking Triggers.
Another difficulty in sustaining cessation may include stress-related and oncologyspecific smoking triggers. Patients diagnosed with cancer often have elevated levels of distress,
leading many long-term and heavy smokers to rely on smoking as a coping strategy and for
mood regulation (McBride & Ostroff, 2003). The National Comprehensive Cancer Network has
identified several periods of increased vulnerability and distress during the course of disease and
treatment (Forsythe, 2013). Included are periods of symptom suspicion, medical and lab work
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ups, determining the stage of cancer progression, diagnosis, awaiting treatment, change in
treatment modality, the end of treatment, hospital discharge following treatment, the stresses of
survivorship, follow-up visits and surveillance, treatment failure, recurrence/disease progression,
advanced cancer, and end of life.
Cancer-related barriers must be addressed with smokers in order to successfully tailor
smoking cessation programs to this vulnerable population. One common barrier is the loss of
coping strategies for dealing with cravings and triggers. For example, a patient who is fatigued
or immobile due to cancer treatment may have a difficult time escaping or avoiding a smoking
trigger. Further, while pharmacologic treatment is often recommended for all patients making a
quit attempt, participants with oral cancers may be unable to use oral forms of NRT (e.g., gum,
lozenge, spray, or inhaler) (Gritz et al., 2006). To date no research exists on the role of distress
as a contributor to smoking triggers in oncology patients.
Health Literacy
For some smokers, health literacy may be of particular importance. In order to instill
change, it might be necessary to provide smokers with information so that they can make
knowledgeable decisions about their smoking (Whyte, Watson, & McIntosh, 2006). In making
the health consequences of smoking salient to smokers, increasing health literacy may encourage
more thoughts about changing smoking behaviors, and further the progression toward cessation.
In the largest randomized control trial of smoking cessation conducted in light smokers, it was
observed that health education outperformed motivational interviewing in promoting cessation
(Ahluwalia et al., 2006). As such, it may be that those who are at lower levels of motivation may
benefit significantly from motivational interviewing, and those at higher levels of motivation to
quit smoking will benefit more from increasing health literacy. Conversely, health literacy may
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be more meaningful to lighter smokers who have lower levels of nicotine addiction and fewer
perceived smoking risks.
The goal of the present study was to expand upon the current literature by exploring
sample characteristics of this understudied population as well as individual differences in cancer
and smoking health literacy, perceived stigma, and oncology-related triggers. Our aim was to
determine the utility of several variables, including ethnicity (African Americans vs.
Caucasians), gender, amount smoked by participants, and whether the participant was in current
treatment or survivorship to predict perceived stigma, health literacy about smoking and cancer,
and oncology-related smoking triggers.
Ethnicity is likely to be particularly important, as there are well-documented systematic
differences in amount smoked, acceptability of smoking, and the effects of tobacco use across
African Americans and Caucasians. Given that African Americans smoke fewer cigarettes
(Trinidad et al., 2009), report less smoking-related perceived stigma (Stuber, Galea, & Link,
2008), and typically demonstrate lower levels of health literacy than Caucasians (Kutner,
Greenburg, Jin, & Paulsen, 2006), we hypothesize that African Americans will report lower
levels of oncology-related triggers, perceived stigma, and health literacy than Caucasians in an
oncology population.
Given that men are more likely to evidence less health literacy about the consequences of
smoking (Von Wagner, Knight, Steptoe, & Wardle, 2007), we hypothesized that men will also
evidence less health literacy about cancer and smoking in an oncology setting than women.
Because no research to date has examined gender effects on stigma and smoking in oncology or
oncology-related triggers, even in a non-oncology setting, we are using this variable on an
exploratory basis.
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Lower level smokers are less likely to be exposed to smoking-related stigma (Castaldelli‐
Maia, Ventriglio, & Bhugra, 2016), report less health literacy and understanding about the
hazards of smoking (Presson, Chassin, & Sherman, 2002), and are less addicted to nicotine than
heavy smokers (Schane, Glantz, & Ling, 2009). Therefore, we hypothesized that lower level
smokers will score lower than heavy smokers on perceived stigma, health literacy, and oncologyrelated triggers to smoke in an oncology population.
Finally, cancer status (currently in treatment vs. in remission/survivorship) will be
assessed on an exploratory basis. Prior studies have looked at stigma in oncology samples within
never smokers and ever smokers (Cho et al., 2013). However, current cancer patient smokers
have not yet been directly compared to cancer survivors. We hypothesized that those currently
in treatment will score higher on perceived stigma, health literacy, and oncology-related triggers
due to the temporal proximity of a cancer diagnosis and cancer treatment when compared with
cancer survivors.
Method
Overview of Procedures
Following approval by the University of Memphis Institutional Review Board, data were
drawn from Oncology Knows to Quit (OK to Quit), a longitudinal study of cigarette use
behaviors and perceptions in a sample of adult oncology patients who ranged in age from 18 to
85 (m = 57.9; SD = 11.50). Participants were recruited and consented into the study when they
initially presented for cancer treatment at the West Cancer Center (WCC). The WCC is a
university-affiliated community cancer center comprised of 14 sites that serve a diverse range of
cancer patients in the Shelby County, TN, southeastern Arkansas, and northwestern Mississippi
region. However, data were only collected at the Germantown, TN, WCC clinic.
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All smoking patients that presented to WCC for cancer treatment answered a range of
health and behavior questions at each visit for clinical purposes. Before patients responded to
survey questions they were asked to consent electronically to their participation in the OK to
Quit study. If a participant consented, they were given a range of survey items consisting of
medical and quality of life items as well as history of smoking behaviors and perceptions about
smoking. Smoking-related survey data remained confidential and were stored on an encrypted
server. Survey data did not become part of the participant’s medical record.
Participants
Adult individuals (18 or older) who were currently receiving treatment for cancer at
WCC were eligible to participate based on the following inclusion criteria: 1) reported being a
current smoker, having smoked at least one cigarette in the past 30 days; 2) were currently or had
previously undergone adjuvant cancer treatment, treatment for cancer recurrence or metastatic
disease, or treatment for blood cancer; 3) had gender data on file, and 4) reported Caucasian or
African American ethnicity. Ethnicity was dichotomized due to small numbers of participants
representing other ethnicities. The sample included 649 participants who were recruited at WCC
from 10/1/2016 to 2/1/2017.
Measures and Coding of Items of Interest
Demographics. Demographic variables were obtained from patient medical records and
included gender [male (0), female (1)], ethnicity [African American (0), Caucasian (1)], age, and
marital status [single (0), married (1), divorced (2), widowed (3)]. Other ethnic groups outside
of African Americans and Caucasians were not included in the present analyses due to
insufficient representation within the current sample.
Medical data. Medical data were obtained from patient records and included cancer
stage [Stage 0 (0), Stage I (1), Stage II (2), Stage III (3), Stage IV (4)] and treatments
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administered [no treatment (0), chemotherapy (1), radiation (2), surgery (3), two treatment
modalities (4), three treatment modalities (5)].
Smoking Status. Participants were asked to answer a number of items that described
their current tobacco use and tobacco use history. They were categorized into those who were
light and intermittent smokers (LITS) (0) and heavy smokers (1). Light smokers were defined as
consuming from 1 cigarette per month up to 10 cigarettes per day, whereas heavy smokers
consumed more than 10 cigarettes per day.
Perceived Stigma. Eight items from the Quality of Life in Neurological Disorders
(Neuro-QOL – Stigma), Short Form were modified to measure participants’ perceptions of self
and publicly enacted negativity, prejudice, and discrimination as a result of cancer-related
manifestations: “Lately because I smoke and now have cancer or have had cancer in the
past...” (1) Some people avoid me; (2) I feel left out of things, (3) People avoid looking at me; (4)
I feel embarrassed; (5) Some people feel uncomfortable with me; (6) I feel embarrassed because
of my physical limitations; (7) People are unkind to me; (8) Some people acted as though it was
my fault I have this illness. These items were each answered on a Likert scale that included the
responses “never” (0), “rarely” (1), “sometimes” (2), “often” (3), and “always” (4).
Oncology-Related Smoking Triggers. Thirteen items were designed to measure
participants’ oncology-related smoking triggers during times of increased distress. Participants
responded to this stem: “I have experienced more frequent or intense cigarette cravings than
usual due to…” Triggers included (1) Finding a suspicious symptom related to cancer; (2)
Having a diagnostic workup related to cancer; (3) Finding out my cancer diagnosis; (4)
Awaiting cancer treatment; (5) A change in my cancer treatment; (6) cancer treatment
complications; (7) The end of cancer treatment; (8) Discharge from the hospital following
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cancer treatment, (9) Transition to cancer survivorship; (10) Medical follow-ups after the end of
cancer treatment; (11) Cancer treatment failure; (12) Cancer coming back/recurrence; and (13)
Cancer getting worse/progressing. These items were each answered on a Likert scale that
included the responses “never” (0), “rarely” (1), “sometimes” (2), “often” (3), “always” (4), and
“not applicable” (-99).
Health Literacy. Five items were designed to measure participants’ health literacy about
smoking and cancer: (1) Smoking cigarettes is related to the development of cancer; (2) People
with cancer who smoke are at higher risk of developing a second cancer than those who don’t
smoke; (3) Cigarette smoking can make cancer treatment not work as well; (4) Cigarette
smoking can make the side effects of cancer treatment worse; (5) Quitting smoking doesn’t really
help a patient’s health once a patient has advanced or metastatic cancer. These items were each
answered on a Likert scale that included the responses “very true” (0), “somewhat true” (1),
“somewhat untrue” (2), and “very untrue” (3).
Approach to Analyses
Descriptive statistics (Table 1) were calculated for demographic, medical, and smoker
characterization variables. Items on each of the three scales were then assessed for internal
consistency using Cronbach’s alpha, at which point it was determined whether alphas would
improve if an item were removed from each of the scales. A factor analysis was then conducted
to determine whether the items included for each of the three concepts of interest (Perceived
Stigma, oncology-Related Smoking Triggers, and Health Literacy) were measuring one
construct.
A factor analysis requires that two assumptions be met. First, the data set must have a
suitable sample size. The present study met both generally accepted recommendations for
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Table 1
Participant Characteristics
Characteristic
Ethnicity

n

%

African American

157

24.2

Caucasian

486

74.9

6

0.9

Male

218

33.6

Female

431

66.4

Missing

0

0.0

Single

142

21.9

Married

327

50.4

Divorced

111

17.1

Widowed

61

9.4

8

1.2

Light and Intermittent

307

47.3

Heavy

243

37.4

99

15.3

Currently in Treatment

408

62.9

In Survivorship

241

37.1

0

0.0

Missing
Gender

Marital Status

Missing
Smoking level

Missing
Patient classification

Missing
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Table 1 (Continued)

Characteristic
Cancer Stage

n

%

0

55

8.5

I

134

20.6

II

104

16.0

III

103

15.9

IV

132

20.3

Missing

121

18.6

106

16.9

13

2

Surgery

119

18.3

Two Modalities

183

28.1

Three Modalities

90

13.9

118

18.2

20

3.1

Treatments Administered
Chemotherapy
Radiation

No Treatment
Missing
Note. (N = 649).

sample size, including having at least 300 participants and having a 10 to 1 ratio of cases to
number of items being factor analyzed (Pallant, 2010). Second, the strength of intercorrelations
among items must be adequate, which is evident when correlations matrix coefficients are
greater than .30 (Pallant, 2010). To assess the factorability of the data the Kaiser-Meyer-Olkin
measure of sampling adequacy, which ranges from 0 to 1, should be at least 0.6. Further,
Bartlett’s Test of Sphericity should be significant (p < .05) to be considered appropriate. In
determining the number of factors to extract, the theoretical model underlying the composition of
the measures was considered. In addition, Cattell’s scree test (Cattell, 1966) was used to plot
13

each of the eigenvalues of the factors. The plot was then inspected to find the point at which the
shape of the line changed direction and became horizontal. All factors above this ‘elbow’ were
retained, as these factors explain the most variance in the dataset (Pallant, 2010). Factor
extraction was not performed, as each scale only produced a single factor (Tabachnick and
Fidell, 2007). As such, all questions within a concept of interest were averaged to obtain an
overall score scale. These variables were then used as the dependent variable for further
analyses.
Due to the data not meeting the assumption of independence for Generalized Estimating
Equations, three separate General Linear Models were utilized. We determined whether scores
on perceived stigma, oncology-related smoking triggers, and health literacy varied by each
independent variable. Independent variables used to predict scores on these three scales included
ethnicity (African American vs. Caucasian), gender (male vs. female), smoking level (LITS vs.
heavy smokers), and cancer status (currently in treatment vs. in survivorship). Means and
standard deviations are reported in Table 2.
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Table 2
Means and Standard Deviations Among Dependent and Independent Variables
Std.
N
PSS

Gender

186

.414

.556

Female

364

.447

.574

African American

138

.454

.623

Caucasian

407

.433

.551

Smoking

LITS

275

.403

.551

Status

Heavy

213

.491

.596

Cancer

In treatment

352

.412

.566

Status

In survivorship

198

.479

.570

Gender

Male

162

2.243

.697

Female

301

2.363

.625

African American

118

2.228

.653

Caucasian

341

2.358

.649

Smoking

LITS

233

2.385

.626

Status

Heavy

181

2.249

.653

Cancer

In treatment

300

2.267

.682

Status

In survivorship

163

2.421

.586

Gender

Male

126

.629

.867

Female

215

1.039

1.065

79

.826

.896

Caucasian

257

.918

1.053

Smoking

LITS

166

.846

1.000

Status

Heavy

145

.943

1.052

Cancer

In treatment

226

.911

1.054

Status

In survivorship

115

.841

.933

Ethnicity

ORSTS

Deviation

Male

Ethnicity

OHLS

Mean

Ethnicity

African American
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Main effects of each independent variable were explored. Interaction effects were not
tested at this time, as the benefits of conducting these exploratory analyses were not seen as
outweighing the subsequent loss of power and ability to detect main effects. Correlations
between all dependent variables and all independent variables included in analyses can be found
in Table 3.
Results
Scale Construction
Perceived Stigma of Smoking Scale - Oncology. We began by conducting analyses to
determine whether the eight questions regarding the perceived stigma of smoking measured a
single construct. All eight questions produced a Cronbach’s alpha of 0.87. Removing any single
scale item would not result in an increased alpha; therefore, all eight items in the scale were
retained.
Prior to performing the factor analysis, the suitability of the data were assessed.
Inspection of the correlation matrix revealed that all coefficients were above 0.3. The KaiserMeyer-Olkin value obtained (0.88) exceeded the recommended value of 0.60 and Bartlett’s Test
of Sphericity reached statistical significance (p < .001), suggesting that the correlation matrix
was appropriate for factor analysis. The eight items were subjected to factor analysis using
principle axis factoring.
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Table 3
Correlations Between Gender, Ethnicity, Smoking Level, Cancer Status, Perceived Stigma, Oncology-Related Smoking Triggers,
and Health Literacy
Gender
Gender

Ethnicity

LITS vs Heavy

Cancer Status

PSS

Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N

Ethnicity

LITS vs
Heavy

Cancer
Status

PSS

OHLS

ORSTS

1

.061

-.113**

.203**

.028

.088

.195**

649

.121
643

.008
550

.000
649

.516
550

.058
463

.000
341

.061

1

.118**

.067

-.015

.087

.039

.121
643

643

.006
546

.092
643

.721
545

.062
459

.482
336

-.113**

.118**

1

-.063

.076

-.105*

.047

.008
550

.006
546

550

.137
550

.093
488

.032
414

.407
311

.203**

.067

-.063

1

.057

.113*

-.033

.000
649

.092
643

.137
550

649

.184
550

.015
463

.547
341

.028

-.015

.076

.057

1

-.091

.448**

.516
550

.721
545

.093
488

.184
550

550

.056
446

.000
338
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Table 3 (Continued)
Gender
OHLS

ORSTS

Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N

Ethnicity

LITS vs
Heavy

Cancer
Status

PSS

.088

.087

-.105*

.113*

-.091

.058
463

.062
459

.032
414

.015
463

.195**

.039

.047

.000
341

.482
336

.407
311

Note. *p < .05 (2-tailed). **p < .05 (2-tailed).
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OHLS

ORSTS
1

-.034

.056
446

463

.552
301

-.033

.448**

-.034

1

.547
341

.000
338

.552
301

341

Factor analysis revealed the presence of one component with an eigenvalue exceeding
one, explaining 53.40% of the variance. An inspection of the scree plot revealed a clear break
after the first component. Using Catell’s scree test, we decided to retain one component. Thus,
we averaged scores across the eight items to obtain an overall measure score. Factor loadings
can be found in Table 4.

Table 4
Factor Loadings for Items on the Perceived Stigma of Smoking Scale - Oncology
Factor 1
People feel uncomfortable with me because I smoke with cancer

.823

Feeling left out of things because I smoke with cancer

.783

People avoid looking because I smoke with cancer

.709

Avoided by people because I smoke with cancer

.684

Embarrassed of physical limitations because I smoke with cancer

.648

People are unkind to me because I smoke with cancer

.640

Feeling embarrassed because I smoke with cancer

.593

People acted as if illness was my fault because I smoke with cancer

.571
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The resulting measure, known as the Perceived Stigma of Smoking Scale – Oncology
(PSSS-O), could range from 0 to 4, with high scores indicating the belief that one experiences a
consistently high amount of stigma due to their oncology patient and smoking status. Those
scoring at the low end of the scale, in contrast, tend to perceive low levels of stigma due to their
oncology patient and smoking status.
Oncology-Related Smoking Triggers Scale. Analyses were then conducted to
determine whether the thirteen questions regarding oncology related triggers were measuring a
single construct. All thirteen questions produced a Cronbach’s alpha of 0.94. Removing any
single scale item would not result in an increased alpha, therefore all thirteen items in the scale
were retained.
Prior to performing the factor analysis, the suitability of the data were assessed.
Inspection of the correlation matrix revealed that all coefficients were above 0.3. The KaiserMeyer-Olkin value obtained (0.83) exceeded the recommended value of 0.60 and Bartlett’s Test
of Sphericity reached statistical significance (p < .001), suggesting that the correlation matrix
was appropriate for factor analysis. The thirteen items were subjected to factor analysis using
principle axis factoring.
Factor analysis revealed the presence of two components with an eigenvalue exceeding
one, with the first explaining 62.26% of the variance and the second explaining 8.46% of the
variance. An inspection of the scree plot revealed a clear break after the first component. Using
Catell’s scree test, we decided to retain one component. Thus, scores across the thirteen items
were averaged to obtain an overall measure score. Factor loadings can be found in Table 5.
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Table 5
Factor Loadings for Items on the Smoking-Related Oncology Triggers Scale
Factor 1
Factor 2
Cigarette cravings due to transition to cancer
.864
survivorship
Cigarette cravings due to the end of treatment

.825

Cigarette cravings due to discharge from hospital

.821

-.362

Cigarette cravings due to treatment
.808

.310

complications
Cigarette cravings due to medical follow-ups

.797

Cigarette cravings due to a change in treatment

.790

Cigarette cravings due to awaiting treatment

.788

Cigarette cravings due to treatment failure

.759

Cigarette cravings due to cancer progressing

.756

Cigarette cravings due to diagnostic workup

.744

Cigarette cravings due to finding out diagnosis

.740

Cigarette cravings due to a suspicious symptom

.725

.449

Cigarette cravings due to cancer recurrence

.593

.400
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-.305

The resulting measure, known as the Oncology-Related Smoking Triggers Scale
(ORSTS), could range from 0 to 4, with high scores indicating the belief that one experiences
high levels of smoking triggers due to cancer symptoms and treatment. Those scoring at the low
end of the scale, in contrast, tend to perceive low levels of smoking triggers due to cancer
symptoms and treatment.
Smoking Health Literacy Scale – Oncology. Finally, analyses were conducted to
determine whether the five questions regarding the health literacy of smoking oncology patients
and those in survivorship were measuring a single construct. All five questions produced a
Cronbach’s alpha of 0.68. However, when one item (“Quitting smoking doesn’t really help a
patient’s health once a patient has advanced or metastatic cancer”) was removed, alpha
increased to 0.83. Because the last item correlated less than 0.30 with the remaining items, and
alpha increased when it was deleted, only the first four items in the scale were retained.
Prior to performing the factor analysis, the suitability of the data were assessed.
Inspection of the correlation matrix revealed that all coefficients were above 0.3. The KaiserMeyer-Olkin value obtained (0.73) exceeded the recommended value of .60 and Bartlett’s Test
of Sphericity reached statistical significance (p < .001), suggesting that the correlation matrix
was appropriate for factor analysis. The four remaining items were subjected to factor analysis
using principle axis factoring.
Factor analysis revealed the presence of one component with an eigenvalue exceeding
one, explaining 65.19% of the variance. An inspection of the scree plot revealed a clear break
after the first component. Using Catell’s scree test, we decided to retain one component. Thus,
we averaged scores across the four items to obtain an overall measure. Factor loadings can be
found in Table 6.
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Table 6
Factor Loadings for Items on the Oncology Health Literacy Scale
Factor 1
Smoking makes cancer treatment not work as well

.839

Smoking makes side effects of treatment worse

.777

Smokers at higher risk of second cancer

.730

Cigarettes related to development of cancer

.580

The resulting measure, known as the Smoking Health Literacy Scale – Oncology (SHLSO), could range from 0 to 3, with high scores indicating a high level of health literacy in terms of
smoking-related outcomes for cancer patients. Those scoring at the low end of the scale, in
contrast, evidenced a low level of health literacy in terms of smoking-related outcomes for
cancer patients.
Individual Differences in Perceived Stigma
A General Linear Model was utilized to determine whether the perceived stigma scores
would vary by the amount a person smoked (LITS vs. heavy smokers), race (Caucasian vs.
African American), gender (male vs. female), and oncology patient status (currently in treatment
vs. survivorship). Toward this end, perceived stigma scores served as the dependent variable
whereas patient characteristics were used as independent variables. Results indicated that among
the main effects of gender, ethnicity, smoking level, and oncology patient status, no main effect
was found to be statistically significant (Table 7).
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Table 7
The Utility of Gender, Ethnicity, Smoking Level, and Cancer Status in Predicting Perceived
Stigma of Smoking Among Oncology Patients
Type III
Sum of
Squares
1.541

df

Mean
Square

F

Sig.

Partial Eta
Squared

4

.385

1.174

0.321

0.01

11.715

1

11.715

35.712

.000

.069

.254

1

.254

.775

0.379

.002

1.098

1

1.098

3.348

0.068

.007

Ethnicity

.072

1

.072

.218

0.641

.000

Current vs Survivor

.251

1

.251

.764

0.383

.002

Error

157.456

480

.328

Total

254.163

485

Corrected Total

158.997

484

Corrected Model
Intercept
Gender
LITS vs Heavy

Note. All p-values were non-significant.

Individual Differences in Oncology-Related Smoking Triggers
Oncology-related smoking trigger scores were then subjected to a General Linear Model
to determine if they varied by the amount a person smoked (LITS vs. heavy smokers), race
(Caucasian vs. African American), gender (male vs. female), and oncology patient status
(currently in treatment vs. survivorship). Toward this end, oncology-related smoking trigger
scores served as the dependent variable while patient characteristics were used as independent
variables.
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Results indicated that among the main effects of gender, ethnicity, smoking level, and
oncology patient status, only the effect of gender was statistically significant, F (1, 303) = 13.44,
p = <.001 (Table 8). Females (m = 1.04) were more likely than males (m = 0.62) to experience
increased levels of smoking triggers when faced with oncology-related symptoms or treatment.

Table 8
The Utility of Gender, Ethnicity, Smoking Level, and Cancer Status in Predicting Smoking-Related
Oncology Triggers Among Oncology Patients
Type III
Sum of
Squares
17.74

df

Mean
Square

F

Sig.

Partial Eta
Squared

4

4.435

4.394

.002

.055

8.912

1

8.912

8.831

.003

.028

13.443

1

13.443

13.32

.000*

.042

LITS vs Heavy

.796

1

.796

.789

.375

.003

Ethnicity

.945

1

.945

.937

.334

.003

3.313

1

3.313

3.283

.071

.011

Error

305.803

303

1.009

Total

571.24

308

323.543

307

Corrected Model
Intercept
Gender

Current vs Survivor

Corrected Total

Note. *p < .001.
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Individual Differences in Smoking Health Literacy in Oncology
Finally, SHLS-O scores were subjected to a General Linear Model to determine if they
varied by the amount a person smoked (LITS vs. heavy smokers), race (Caucasian vs. African
American), gender (male vs. female), and oncology patient status (currently in treatment vs.
survivorship). Toward this end, SHLS-O scores served as the dependent variable while patient
characteristics were used as independent variables.
Results indicated that of the four effects entered, the effects of smoking status, F (1, 406)
= 4.97, p = .026, and ethnicity, F (1, 406) = 6.47, p = .011, were statistically significant (Table
9). Caucasian oncology patients (m = 2.36) were more likely than African American oncology
patients (m = 2.23) to experience higher levels of health literacy in terms of smoking-related
outcomes. Further, light and intermittent smoking oncology patients (m = 2.39) were more likely
than heavy smoking oncology patients (m = 2.25) to be more health literate in terms of smokingrelated outcomes. Participants who were in survivorship (m = 2.43) were more likely than those
currently in treatment (m = 2.27) to experience higher levels of health literacy, though this trend
did not reach statistical significance (p = .054).
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Table 9

The Utility of Gender, Ethnicity, Smoking Level, and Cancer Status in Predicting SmokingRelated Health Literacy Among Oncology Patients
Type III
Mean
Partial Eta
Sum of
df
F
Sig.
Square
Squared
Squares
Corrected Model
6.558
4
1.64
4.146
.003
.039
Intercept

335.573

1

335.573

848.488

.000

.676

.126

1

.126

.318

.573

.001

LITS vs Heavy

1.964

1

1.964

4.967

.026*

.012

Ethnicity

2.558

1

2.558

6.468

.011*

.016

Current vs Survivor

1.477

1

1.477

3.734

.054

.009

Error

160.571

406

.395

Total

2395.472

411

167.129

410

Gender

Corrected Total

Note. *p < .05.

Discussion
To date little research has been directed toward smoking oncology patients and survivors,
who are often medically fragile and an understudied population. Learning more about the risk
and protective factors for these patients is an important first step for prevention and intervention,
and this was a primary aim of this study. Toward this end, we created three scales to better
measure smoking perceptions and behaviors in this population.
Individual Differences in Perceived Stigma. First was the PSSS-O, an eight-item
measure rated on a four-point Likert scale that was developed as a modified version of the
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Neuro-QOL (Stigma) Short Form. Each item measured the perception of stigma by participants
as a result of both being a smoker and a current or former cancer patient. Items focused on
dimensions such as social aspects of stigma (e.g., being avoided by people, blame from others,
social distance) and internalization (e.g., being embarrassed, feeling left out). The PSSS-O is
scored so that high values represent a patient’s belief that s/he is experiencing stigma because of
being both a smoker and a cancer patient. Subsequent analyses revealed that the scale
demonstrated strong internal consistency and yielded a single factor. Thus, participants were
consistent in their responses, and the scale measured a single construct. The strong internal
consistency of PSSS-O scale items aligns with prior research on the Neuro-QOL, which has
demonstrated high internal consistency (0.85-0.97) across a range of medically ill populations
(Cella et al., 2012).
We then explored whether individual differences emerged in the measurement of stigma.
Specifically, we used gender, race, how much a participant smoked, and oncology status to
predict PSSS-O scores. Our results identified no statistically significant main effects among
gender, ethnicity, smoking level, or oncology patient status. Surprisingly, participants
demonstrated low scores on perceived stigma overall. Thus, oncology patients who smoked
seemed to experience little stigma, suggesting that friends and family may choose not to address
a cancer patient’s tobacco use. Further, social supports may not recognize the deleterious effects
on smokers once they have already been diagnosed with cancer or once they are in remission.
Given that smokers tend to create social systems that include other smokers, our participants
were more likely to have family or social contacts that were smokers themselves. For this reason,
friends and/or family members of oncology patients may be unlikely to point out that tobacco
use could further damage patients’ health. Although there is some evidence that stigma can lead
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to reductions in smoking, there may also be negative consequences of it. For example, oncology
patients subjected to criticism of their smoking might experience more difficulty quitting caused
by delays in seeking cessation treatment, loss of self-efficacy for quitting, defensiveness, and
increased stress (Evans-Polce, Castaldelli-Maia, Schomerus, & Evans-Lacko, 2015). Perhaps
lower levels of perceived stigma are protective for overall mental health in this population,
despite serving as a risk factor for continued smoking. Alternatively, there may be a different
explanation for the low scores demonstrated by this sample. Perceived stigma may be an
emotionally difficult experience for patients, making them less likely to accurately report this
problem.
Regardless of patient characteristics, participants evidenced similar levels of perceived
stigma. This finding indicates that the stigma scale developed for this study is stable across
multiple oncology patient characteristics, including gender, ethnicity, smoking level, and
oncology status. Therefore, the scale can likely be used in future research across a range of
participants varying on these constructs.
Individual Differences in Oncology-Related Smoking Triggers. The second scale
established to better understand smoking behaviors in an oncology sample was the ORSTS.
These items were developed in response to clinical information gathered from oncology patients,
who often disclosed in smoking cessation appointments that they experienced increased cravings
and triggers when facing cancer-related stress. Each of the 13 items was rated on a four-point
Likert scale. Items measured the level of cigarette cravings experienced by participants during
times of increased distress that were related to being a cancer patient, and focused on facets such
as symptoms, workups, diagnosis, treatment, and survivorship. The ORSTS is scored so that
high values represent more frequent or intense cigarette cravings when navigating the various
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aspects of oncology. Subsequent analyses revealed strong internal consistency and yielded a
single factor.
Analyses were conducted to determine whether gender, race, how much a participant
smoked, and oncology status related to ORSTS scores. Our results identified one main effect of
gender, but no statistically significant main effects among ethnicity, smoking level, or oncology
patient status. Participants experienced low levels of perceived oncology-related triggers overall,
but females were more likely than males to report increased triggers when faced with oncologyrelated stressors. Due to these results, future research and analyses using the ORSTS to predict
outcomes could partial out the variability related to gender. As oncology-related smoking
trigger scores have been shown to be affected by gender, this approach would allow for a more
powerful test.
Ng & Jeffery (2003) found that both men and women increase their level of smoking
during times of increased perceived stress. However, women evidence more cigarette cravings,
physiological arousal, and stress with greater negative emotions in response to stressful
situations (Saladin et al., 2012). Consistent with the literature women in the current study
experienced more smoking triggers in response to cancer-related situations, potentially indicating
a need for increased coping skills and support. However, it was unclear whether the higher level
of triggers reported by women in the present study actually led to more smoking behaviors as a
result of increased triggers.
Individual Differences in Smoking Health Literacy in Oncology. The third scale
established to better understand smoking behaviors in an oncology sample was the SHLS-O,
with four items rated on a three-point Likert scale. Each item measured the level of health
literacy reported by participants about smoking and cancer. Items focused on aspects of health
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as related to smoking such as the development of cancer and treatment outcomes. The SHLS-O
is scored so that high values represent high levels of knowledge about the health consequences of
smoking as related to cancer. Subsequent analyses revealed strong internal consistency and
yielded a single factor.
Further analysis revealed that individual differences emerged in how adults responded to
the SHLS-O. Specifically, we used gender, race, how much a participant smoked, and oncology
status to predict SHLS-O scores. Our results identified the statistically significant main effects
of ethnicity and smoking level. Consistent with our hypotheses, Caucasian oncology patients (m
= 2.36) were more likely than African American oncology patients to experience higher levels of
health literacy in terms of smoking-related outcomes. Contrary to our hypothesis, light and
intermittent smoking oncology patients had higher levels of health literacy than heavily smoking
oncology patients. There were no significant main effects of gender or patient status (in
treatment versus in survivorship).
Health literacy is an especially important construct when considering a sample of
medically fragile oncology patients, as lack of health literacy has been demonstrated to be an
independent risk factor for relapse of smoking (Stewart et al., 2014). Fortunately, participants in
this sample experienced high levels of health literacy overall about the health consequences of
smoking and cancer. Perhaps this finding reflects providers and staff educating patients about
their health, including a focus on how smoking impacts treatment outcomes. Patients may also
have had prior knowledge about the risks of smoking and cancer due to public health messages.
However, it is not surprising that Caucasians evidenced higher levels of health literacy than
African Americans given previous research. African Americans have been shown to have lower
levels of health literacy about smoking (Stewart et al., 2013), even when controlling for SES
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factors (Braveman et al., 2005). As such, health literacy may play an important role in ethnic
disparities in terms of health outcomes (Berkman, Sheridan, Donahue, Halpern, & Crotty, 2011).
Further, LITS had a higher level of health literacy than heavy smokers. These results are
surprising given previous research showing that lower-level smokers may underestimate the
negative consequences of smoking (Farrell, Robinson, & Ali, 2015). However, the sample of
older adult oncology patients in the present study differed considerably from the community
sample of young adults utilized by Farrell and colleagues. It is possible that many LITS in the
current study were former heavy smokers who utilized health information about smoking and
cancer to decrease their use, thus shifting them from heavy smoking to light or intermittent
smoking. LITS may have less motivation to quit even when knowledgeable about health
consequences and may benefit from motivational interviewing strategies (Ahluwalia et al.,
2006).
Despite its novelty, this study has several limitations. First, participants were drawn from
an urban, mid-South area and results may not be generalizable to other populations. In addition,
further research is needed on the PSSS-O, ORSTS, and SHLS-O. Future directions should
include estimates of their test-retest reliabilities and performance with other samples of oncology
patients. Further, this correlational study cannot provide information about causality for
significant main effects. Participants for this study were also self-selected, which may have
affected the results (e.g., those who felt the most stigma about their smoking did not participate
due to the desire to avoid further guilt and shame). Finally, participants may have underreported
their level of perceived stigma and smoking triggers due to the testing environment. Answering
sensitive questions in their physician’s office may have influenced patients to be less
forthcoming than if they had been asked in a research setting.
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Several implications of this research should be acknowledged. First, each scale
demonstrated strong internal consistency in an oncology patient sample, making them
appropriate for use in future research as well as confirming their utility in a clinical setting.
Second, cancer patients experienced low levels of stigma overall about their smoking behaviors,
which may result in better mental health but also less internal and external pressure to quit.
Third, women were more likely than men to experience increased triggers to smoke when faced
with oncology-related stress. They may need more support from medical and mental health staff
to address cravings and to ensure their cigarette consumption does not increase. Fourth,
smoking-related health literacy levels were high overall, indicating that patients are aware of the
health consequences of smoking. However, these participants continued to smoke even though
they realized that they are less likely to have successful treatment outcomes. Further, health
literacy varied by both ethnicity and smoking level, but patients scored high on health literacy
overall. This may indicate the need for motivational enhancement strategies to increase
motivation to quit among African Americans and heavier smokers. Finally, whether or not a
patient was currently receiving treatment or in survivorship did not predict scores on any of the
three scales.

33

References
Ahluwalia, J. S., Okuyemi, K., Nollen, N., Choi, W. S., Kaur, H., Pulvers, K., et al. (2006). The
effects of nicotine gum and counseling among African American light smokers: A 2 x 2
factorial design. Addiction, 101, 883-891.
Bassett, J. C., Gore, J. L., Chi, A. C., Kwan, L., McCarthy, W., Chamie, K., & Saigal, C. S.
(2012). Impact of a bladder cancer diagnosis on smoking behavior. Journal of Clinical
Oncology: Official Journal of the American Society of Clinical Oncology, 30(15), 18711878. doi:10.1200/JCO.2011.36.6518 [doi]
Braveman, P. A., Cubbin, C., Egerter, S., Chideya, S., Marchi, K. S., Metzler, M., & Posner, S.
(2005). Socioeconomic status in health research: one size does not fit all. Jama, 294(22),
2879-2888.
Berkman, N. D., Sheridan, S. L., Donahue, K. E., Halpern, D. J., & Crotty, K. (2011). Low
health literacy and health outcomes: an updated systematic review. Annals of internal
medicine, 155(2), 97-107.
Burns, D., Garfinkel, L., & Samet, J. (1997). National cancer institute. smoking and tobacco
control monograph no. 8: Changes in cigarette-related disease risks and their implication
for prevention. Bethesda, MD: US department of health and human services. Public
Health Service, National Institutes of Health, 602.
Carter‐Harris, L. (2015). Lung cancer stigma as a barrier to medical help‐seeking behavior:
Practice implications. Journal of the American Association of Nurse Practitioners, 27(5),
240-245.

34

Castaldelli‐Maia, J. M., Ventriglio, A., & Bhugra, D. (2016). Tobacco smoking: From ‘glamour
‘to ‘stigma’. A comprehensive review. Psychiatry and clinical neurosciences, 70(1), 2433.
Cattell, R. B. (1966). The scree test for the number of factors. Multivariate behavioral research,
1(2), 245-276.
Cella, D., Lai, J. S., Nowinski, C. J., Victorson, D., Peterman, A., Miller, D., ... & Reder, A. T.
(2012). Neuro-QOL Brief measures of health-related quality of life for clinical research
in neurology. Neurology, 78(23), 1860-1867.
Centers for Disease Control and Prevention (CDC). (2002). Cigarette smoking among adults-united states, 2000. MMWR. Morbidity and Mortality Weekly Report, 51(29), 642-645.
Centers for Disease Control and Prevention (CDC). (2008). Smoking-attributable mortality,
years of potential life lost, and productivity losses--United States, 2000-2004. MMWR.
Morbidity and Mortality Weekly Report, 57(45), 1226-1228.
Centers for Disease Control and Prevention (CDC). (2011). Quitting smoking among adults-United States, 2001-2010. MMWR. Morbidity and Mortality Weekly Report, 60(44),
1513-1519. doi:mm6044a2 [pii]
Centers for Disease Control and Prevention (CDC). (2015). Cancer. FastStats, Diseases and
Conditions. Retrieved from http://www.cdc.gov/nchs/fastats/cancer.htm.
Chapple, A., Ziebland, S., & McPherson, A. (2004). Stigma, shame, and blame experienced by
patients with lung cancer: qualitative study. BMJ, 328(7454), 1470.
Chelghoum, Y., Danaila, C., Belhabri, A., Charrin, C., Le, Q. H., Michallet, M., . . . Thomas, X.
(2002). Influence of cigarette smoking on the presentation and course of acute myeloid

35

leukemia. Annals of Oncology: Official Journal of the European Society for Medical
Oncology / ESMO, 13(10), 1621-1627.
Chen, C., Shun, C., Huang, K., Huang, C., Tsai, Y., Yu, H., & Pu, Y. (2007). Stopping smoking
might reduce tumour recurrence in nonmuscle‐invasive bladder cancer. BJU
International, 100(2), 281-286.
Cho, J., Choi, E. K., Kim, S. Y., Shin, D. W., Cho, B. L., Kim, C. H., ... & Park, J. H. (2013).
Association between cancer stigma and depression among cancer survivors: a nationwide
survey in Korea. Psycho‐Oncology, 22(10), 2372-2378.
Cobb, N. K., Graham, A. L., Bock, B. C., Papandonatos, G., & Abrams, D. B. (2005). Initial
evaluation of a real world Internet smoking cessation system. Nicotine & Tobacco
Research, 7, 207-216.
Day, G. L., Blot, W. J., Shore, R. E., McLaughlin, J. K., Austin, D. F., Greenberg, R. S., . . .
Schoenberg, J. B. (1994). Second cancers following oral and pharyngeal cancers: Role of
tobacco and alcohol. Journal of the National Cancer Institute, 86(2), 131-137.
Des Rochers, C., Dische, S., & Saunders, M. (1992). The problem of cigarette smoking in
radiotherapy for cancer in the head and neck. Clinical Oncology, 4(4), 214-216.
Duffy, S. A., Khan, M. J., Ronis, D. L., Fowler, K. E., Gruber, S. B., Wolf, G. T., & Terrell, J. E.
(2008). Health behaviors of head and neck cancer patients the first year after diagnosis.
Head & Neck, 30(1), 93-102.
Evans-Polce, R. J., Castaldelli-Maia, J. M., Schomerus, G., & Evans-Lacko, S. E. (2015). The
downside of tobacco control? Smoking and self-stigma: a systematic review. Social
Science & Medicine, 145, 26-34.

36

Farrell, A. S., Robinson, L. A., & Ali, J. S. (2015, February). What do young adults consider to
be “smoking?” A study of individual differences. Poster presented at the annual meeting of
the Society for Research on Nicotine and Tobacco, Philadelphia, PA.
Forsythe, L. P., Rowland, J. H., Padgett, L., Blaseg, K., Siegel, S. D., Dingman, C. M., & Gillis,
T. A. (2013). The cancer psychosocial care matrix: A community‐derived evaluative tool for
designing quality psychosocial cancer care delivery. Psycho‐oncology, 22(9), 1953-1962.
Geyer, S. M., Morton, L. M., Habermann, T. M., Allmer, C., Davis, S., Cozen, W., . . . Maurer,
M. J. (2010). Smoking, alcohol use, obesity, and overall survival from non‐Hodgkin
lymphoma. Cancer, 116(12), 2993-3000.
Gritz, E. R., Fingeret, M. C., Vidrine, D. J., Lazev, A. B., Mehta, N. V., & Reece, G. P. (2006).
Successes and failures of the teachable moment. Cancer, 106(1), 17-27.
Jamal, A., Agaku, I. T., O’Connor, E., King, B. A., Kenemer, J. B., & Neff, L. (2014). Current
cigarette smoking among adults—United states, 2005–2013. MMWR Morb Mortal Wkly
Rep, 63(47), 1108-1112.
Kawahara, M., Ushijima, S., Kamimori, T., Kodama, N., Ogawara, M., Matsui, K., . . . Furuse,
K. (1998). Second primary tumours in more than 2-year disease-free survivors of small-cell
lung cancer in japan: The role of smoking cessation. British Journal of Cancer, 78(3), 409412.
Kearney, D. J., Lee, T. H., Reilly, J., DeCamp, M. M., & Sugarbaker, D. J. (1994). Assessment
of operative risk in patients undergoing lung resection. importance of predicted pulmonary
function. CHEST Journal, 105(3), 753-759.
Kehlet, M., Heeseman, S., Tønnesen, H., & Schroeder, T. V. (2015). Perioperative smoking
cessation in vascular surgery: challenges with a randomized controlled trial. Trials, 16(1), 1.

37

Kobrinsky, N. L., Klug, M. G., Hokanson, P. J., Sjolander, D. E., & Burd, L. (2003). Impact of
smoking on cancer stage at diagnosis. Journal of Clinical Oncology: Official Journal of the
American Society of Clinical Oncology, 21(5), 907-913.
Kutner, M., Greenburg, E., Jin, Y., & Paulsen, C. (2006). The Health Literacy of America's
Adults: Results from the 2003 National Assessment of Adult Literacy. NCES 2006-483.
National Center for Education Statistics.
Marlow, L. A., Waller, J., & Wardle, J. (2015). Does lung cancer attract greater stigma than
other cancer types? Lung Cancer, 88(1), 104-107.
Martinez, E., Tatum, K. L., Weber, D. M., Kuzla, N., Pendley, A., Campbell, K., . . . Schnoll, R.
A. (2009). Issues related to implementing a smoking cessation clinical trial for cancer
patients. Cancer Causes & Control, 20(1), 97-104.
McBride, C. M., & Ostroff, J. S. (2003). Teachable moments for promoting smoking cessation:
the context of cancer care and survivorship. Cancer control, 10(4), 325-333.
Nayan, S., Gupta, M. K., Strychowsky, J. E., & Sommer, D. D. (2013). Smoking cessation
interventions and cessation rates in the oncology population an updated systematic review
and meta-analysis. Otolaryngology--Head and Neck Surgery, 149(2), 200-211.
Ng, D. M., & Jeffery, R. W. (2003). Relationships between perceived stress and health behaviors
in a sample of working adults. Health Psychology, 22(6), 638.
Ostroff, J. S., Burkhalter, J. E., Cinciripini, P. M., Li, Y., Shiyko, M. P., Lam, C. Y., ... &
Manna, R. (2014). Randomized trial of a presurgical scheduled reduced smoking
intervention for patients newly diagnosed with cancer. Health Psychology, 33(7), 737.
Pallant, J. (2013). SPSS survival manual. McGraw-Hill Education (UK).

38

Parsons, A., Daley, A., Begh, R., & Aveyard, P. (2010). Influence of smoking cessation after
diagnosis of early stage lung cancer on prognosis: Systematic review of observational
studies with meta-analysis. BMJ (Clinical Research Ed.), 340, b5569.
doi:10.1136/bmj.b5569 [doi]
Presson, C. C., Chassin, L., & Sherman, S. J. (2002). Psychosocial antecedents of tobacco
chipping. Health Psychology, 21(4), 384.
Rosenstock, I. M., Strecher, V. J., & Becker, M. H. (1988). Social learning theory and the health
belief model. Health Education Quarterly, 15, 175-183.
Saladin, Michael E., Kevin M. Gray, Matthew J. Carpenter, Steven D. LaRowe, Stacia M.
DeSantis, and Himanshu P. Upadhyaya. "Gender differences in craving and cue reactivity to
smoking and negative affect/stress cues." The American journal on addictions 21, no. 3
(2012): 210-220.
Schane, R. E., Glantz, S. A., & Ling, P. M. (2009). Nondaily and social smoking: an increasingly
prevalent pattern. Archives of Internal Medicine, 169(19), 1742-1744.
Spitz, M. R., Fueger, J. J., Chamberlain, R. M., Goepfert, H., & Newell, G. R. (1990). Cigarette
smoking patterns in patients after treatment of upper aerodigestive tract cancers. Journal of
Cancer Education, 5(2), 109-113.
Stewart, D. W., Adams, C. E., Cano, M. A., Correa-Fernández, V., Li, Y., Waters, A. J., ... &
Vidrine, J. I. (2013). Associations between health literacy and established predictors of
smoking cessation. American journal of public health, 103(7), e43-e49.
Stewart, D. W., Cano, M. Á., Correa-Fernández, V., Spears, C. A., Li, Y., Waters, A. J., ... &
Vidrine, J. I. (2014). Lower health literacy predicts smoking relapse among

39

racially/ethnically diverse smokers with low socioeconomic status. BMC Public
Health, 14(1), 716.

Stuber, J., Galea, S., & Link, B. G. (2008). Smoking and the emergence of a stigmatized social
status. Social science & medicine, 67(3), 420-430.
Tabachnick, B. G., & Fidell, L. S. (2007). Using multivariate statistics. Allyn & Bacon/Pearson
Education.
Trinidad, D. R., Perez-Stable, E. J., Emery, S. L., White, M. M., Grana, R. A., & Messer, K. S.
(2009). Intermittent and light daily smoking across racial/ethnic groups in the United
States. Nicotine and Tobacco Research, 11, 203-210.
US Department of Health and Human Services. (2004). The health consequences of smoking: A
report of the surgeon general. Atlanta, GA: US Department of Health and Human
Services, Centers for Disease Control and Prevention, National Center for Chronic
Disease Prevention and Health Promotion, Office on Smoking and Health, 62
US Department of Health and Human Services. (2010a). How tobacco smoke causes disease:
The biology and behavioral basis for smoking-attributable disease: A report of the
surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers
for Disease Control and Prevention, National Center for Chronic Disease Prevention
and Health Promotion, Office on Smoking and Health, 2
US Department of Health and Human Services. (2010b). A report of the surgeon general: How
tobacco smoke causes disease: What it means to you. US department of health and
human services, centers for disease control and prevention. National Center for Chronic
Disease Prevention and Health Promotion, Office on Smoking and Health,

40

US Department of Health and Human Services. (2014). The health consequences of Smoking—
50 years of progress: A report of the surgeon general. Atlanta, GA: US Dept of health and
human services, centers for disease control and prevention. National Center for Chronic
Disease Prevention and Health Promotion, Office on Smoking and Health.
Http://www.Surgeongeneral.gov/library/reports/50-Years-of-progress/full-Report.Pdf
(Accessed 5 November 2015)
Von Wagner, C., Knight, K., Steptoe, A., & Wardle, J. (2007). Functional health literacy and
health-promoting behaviour in a national sample of British adults. Journal of epidemiology
and community health, 61(12), 1086-1090.
Wein, R. O. (2009). Preoperative smoking cessation: Impact on perioperative and long-term
complications. Archives of Otolaryngology–Head & Neck Surgery, 135(6), 597-601.
Whyte, R. E., Watson, H. E., & McIntosh, J. (2006). Nurses’ opportunistic interventions with
patients in relation to smoking. Journal of Advanced Nursing, 55, 568-577.

41

Appendix A
All Participants
Have you ever smoked a cigarette, even once?
 Yes (1)
 No (0)
Have you smoked a cigarette in the past 30 days?
 Yes (1)
 No (0)
Quitters
How long ago did you quit smoking cigarettes?
 Less than 6 months ago (0)
 6 months - less than 1 year ago (1)
 1 - 5 years ago (2)
 6 - 10 years ago (3)
 11 - 15 years ago (4)
 16 - 20 years ago (5)
 21 - 25 years ago (6)
 26 - 30 years ago (7)
 More than 30 years ago (8)
How long did you smoke cigarettes before you quit?
 Less than 6 months ago (0)
 6 months - less than 1 year ago (1)
 1 - 5 years ago (2)
 6 - 10 years ago (3)
 11 - 15 years ago (4)
 16 - 20 years ago (5)
 21 - 25 years ago (6)
 26 - 30 years ago (7)
 More than 30 years ago (8)
How many times did you try to quit before you quit smoking cigarettes for good?
 0 (0)
 1 - 5 (1)
 6 - 10 (2)
 11 - 15 (3)
 16 or more (4)
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Select all methods of quitting that you have previously used:
 Nicotine patch (0)
 Nicotine gum (1)
 Nicotine inhaler (2)
 Nicotine nasal spray (3)
 Stopping immediately/cold turkey (4)
 Slowly cutting back (5)
 Electronic cigarettes (6)
 Zyban (Bupropion, Wellbutrin) (7)
 Varenicline (Chantix) (8)
 Behavioral counseling (9)
Cancer was my main reason for quitting
 Very true (0)
 Somewhat true (1)
 Somewhat untrue (2)
 Very untrue (3)
Smokers
In the past 30 days how many cigarettes did you smoke?
 More than 40 per day (0)
 21 - 40 per day (1)
 11 - 20 per day (2)
 1 - 10 per day (3)
 1 - 6 per week (4)
 1 - 3 per month (5)
How long have you been smoking cigarettes?
 6 months - < 1 year (0)
 1 – 5 years (1)
 6 – 10 years (2)
 11 – 15 years (3)
 16 – 20 years (4)
 21 – 25 years (5)
 26 – 30 years (6)
 >30 years (7)
Do you live with any other smokers?
 I don’t live with any other smokers (0)
 My spouse (1)
 My child/children (2)
 Another family member (3)
 Other (4)
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Are you currently thinking about quitting cigarettes?
 Yes, within the next 30 days (0)
 Yes, within the next 6 months (1)
 No, not thinking of quitting (2)
How many times have you tried quitting cigarettes for at least 24 hours?
 0 (0)
 1 - 5 (1)
 6 - 10 (2)
 11 - 15 (3)
 16 or more (4)
Select all methods of quitting that you have previously used:Nicotine patch (0)










Nicotine gum (1)
Nicotine inhaler (2)
Nicotine nasal spray (3)
Stopping immediately/cold turkey (4)
Slowly cutting back (5)
Electronic cigarettes (6)
Zyban (Bupropion, Wellbutrin) (7)
Varenicline (Chantix) (8)
Behavioral counseling (9)

How soon after waking do you smoke your first cigarette?
 Within 5 minutes (0)
 5– 30 minutes (1)
 31-60 minutes (2)
 More than 60 minutes (3)
Do you find it difficult to refrain from smoking in places where it is forbidden? E.g. Church,
library, the movies, on an airplane, etc.
 Yes (1)
 No (0)
Which cigarette would you most hate to give up?
 The first one of the day (0)
 Any other (1)
Do you smoke more frequently in the morning?
 Yes (1)
 No (0)
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Do you smoke even if you are sick in bed most of the day?
 Yes (1)
 No (0)
Lately because I smoke and now have/had cancer...
Some people avoid me
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
Lately because I smoke and now have/had cancer...
I feel left out of things
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
Lately because I smoke and now have/had cancer...
People avoid looking at me
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
Lately because I smoke and now have/had cancer...
I feel embarrassed
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
Lately because I smoke and now have/had cancer...
Some people feel uncomfortable with me
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
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Lately because I smoke and now have/had cancer...
I feel embarrassed because of my physical limitations
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
Lately because I smoke and now have/had cancer...
People are unkind to me
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
Lately because I smoke and now have/had cancer...
Some people acted as though it was my fault I have this illness
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
I have experienced more cigarette cravings than usual due to…
Finding a suspicious symptom related to cancer
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
Having a diagnostic workup related to cancer
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
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I have experienced more cigarette cravings than usual due to…
Finding out my cancer diagnosis
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
Awaiting cancer treatment
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
A change in my cancer treatment
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
Cancer treatment complications
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
The end of cancer treatment
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
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I have experienced more cigarette cravings than usual due to…
Discharge from the hospital following cancer treatment
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
Transition to cancer survivorship
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
Medical follow-ups after the end of cancer treatment
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
Cancer treatment failure
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
I have experienced more cigarette cravings than usual due to…
Cancer coming back/recurrence
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
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I have experienced more cigarette cravings than usual due to…
Cancer getting worse/progressing
 Never (0)
 Rarely (1)
 Sometimes (2)
 Often (3)
 Always (4)
 Not applicable (-99)
Has your primary oncologist ever talked to you about smoking?
 No (0)
 Yes (1)
Smoking cigarettes is related to the development of cancer
 Very true (0)
 Somewhat true (1)
 Somewhat untrue (2)
 Very untrue (3)
People with cancer who smoke are at higher risk of developing a second cancer than those who
don’t smoke
 Very true (0)
 Somewhat true (1)
 Somewhat untrue (2)
 Very untrue (3)
Cigarette smoking can make cancer treatment not work as well
 Very true (0)
 Somewhat true (1)
 Somewhat untrue (2)
 Very untrue (3)
Cigarette smoking can make the side effects of cancer treatment worse
 Very true (0)
 Somewhat true (1)
 Somewhat untrue (2)
 Very untrue (3)
Quitting smoking doesn’t really help a patient’s health once a patient has advanced or metastatic
cancer
 Very true (0)
 Somewhat true (1)
 Somewhat untrue (2)
 Very untrue (3)
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Patients who get help with quitting are much more likely to stop using nicotine and tobacco
altogether. To support your health we offer these services free of charge to all of our patients.
How would you like to receive support?
 I would like to be contacted to schedule an in person appointment (0)
 By telephone (1)
 By mail (2)
 I would not like to be contacted (3)
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